Neuronetics ( (STIM) ) has released its Q2 earnings. Here is a breakdown of the information Neuronetics presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Neuronetics, Inc. is a leading company in the neuroscience sector, specializing in non-invasive treatments for mental health conditions such as major depressive disorder and obsessive-compulsive disorder. The company’s flagship product, the NeuroStar Advanced Therapy System, utilizes transcranial magnetic stimulation to stimulate specific brain areas, offering an alternative to traditional antidepressant medications. Neuronetics also operates treatment centers across the U.S., providing in-office therapies.
In its latest earnings report for the quarter ending June 30, 2025, Neuronetics reported a significant increase in revenues, reaching $38.1 million compared to $16.5 million in the same period last year. This growth is largely attributed to the acquisition of Greenbrook TMS Inc., which expanded the company’s treatment center operations and contributed to the revenue surge.
Key financial highlights include a gross profit of $17.8 million, up from $12.2 million in the previous year, despite an increase in operating expenses to $25.8 million. The company reported a net loss of $9.8 million, consistent with the previous year’s loss, reflecting ongoing investments in sales, marketing, and administrative functions.
Looking ahead, Neuronetics’ management remains optimistic about the company’s financial trajectory, driven by anticipated revenue growth from existing and newly acquired product lines. The company is focused on realizing synergies from the Greenbrook acquisition and improving cost efficiencies, which are expected to enhance operational performance in the coming quarters.